ZHEJIANG ZHENYUAN announced that from January 1, 2024, to December 31, 2024, the net profit attributable to shareholders of the listed company is expected to be between 26.1256 million yuan and 36.5759 million yuan, a decrease of 55.2% to 68% compared to the same period last year. The net profit after deducting non-recurring gains and losses is expected to be between 20.3352 million yuan and 28.4693 million yuan, a decrease of 63.6% to 74% compared to the same period last year. The basic earnings per share are expected to be between 0.08 yuan/share and 0.11 yuan/share. The company's performance changes are mainly due to factors such as the contraction of the pharmaceutical wholesale business scale, an increase in accounts receivable, and an increase in financial expenses
